BR112018068412A2 - composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral - Google Patents

composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral

Info

Publication number
BR112018068412A2
BR112018068412A2 BR112018068412A BR112018068412A BR112018068412A2 BR 112018068412 A2 BR112018068412 A2 BR 112018068412A2 BR 112018068412 A BR112018068412 A BR 112018068412A BR 112018068412 A BR112018068412 A BR 112018068412A BR 112018068412 A2 BR112018068412 A2 BR 112018068412A2
Authority
BR
Brazil
Prior art keywords
killing
compound
pharmaceutical composition
tumor cell
myelodysplastic syndrome
Prior art date
Application number
BR112018068412A
Other languages
English (en)
Inventor
Wei Sheng
List Alan
Lawrence Nicholas
Original Assignee
H. Lee Moffitt Cancer Center And Research Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lee Moffitt Cancer Center And Research Institute, Inc. filed Critical H. Lee Moffitt Cancer Center And Research Institute, Inc.
Publication of BR112018068412A2 publication Critical patent/BR112018068412A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pyrane Compounds (AREA)

Abstract

são divulgados derivados de icariin. são divulgados compostos com a fórmula i-v, como definidos neste documento. métodos de utilização destes compostos para o tratamento de câncer e inflamação são também divulgados.
BR112018068412A 2016-03-11 2017-03-13 composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral BR112018068412A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662306694P 2016-03-11 2016-03-11
PCT/US2017/022030 WO2017156520A1 (en) 2016-03-11 2017-03-13 Icariin and icaritin derivatives

Publications (1)

Publication Number Publication Date
BR112018068412A2 true BR112018068412A2 (pt) 2019-01-22

Family

ID=59789762

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018068412A BR112018068412A2 (pt) 2016-03-11 2017-03-13 composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral

Country Status (10)

Country Link
US (1) US20200115358A1 (pt)
EP (1) EP3426242A4 (pt)
JP (1) JP2019507796A (pt)
KR (1) KR20180120746A (pt)
CN (1) CN109310666A (pt)
AU (1) AU2017230119A1 (pt)
BR (1) BR112018068412A2 (pt)
CA (1) CA3017366A1 (pt)
MX (1) MX2018010993A (pt)
WO (1) WO2017156520A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201815045D0 (en) * 2018-09-14 2018-10-31 Univ Ulster Bispecific antibody targeting IL-1R1 and NLPR3
CN112438974B (zh) * 2019-09-03 2023-11-21 鲁南制药集团股份有限公司 淫羊藿苷元在制备预防或治疗溃疡性结肠炎药物中的应用
CN110522745A (zh) * 2019-09-06 2019-12-03 武汉大学 水合淫羊藿素在制备抑制stat3信号通路及防治口腔癌的药物中的应用
EP4119139A4 (en) * 2020-03-10 2024-03-20 Lunan Pharmaceutical Group Corporation MEDICAL USE OF ANYHDROICARITIN
AR121719A1 (es) 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
US20230293483A1 (en) * 2020-09-25 2023-09-21 Industry-Academic Coorperation Foundation Daegu Haany University Composition for preventing or treating liver disease, comprising icaritin and quercetin
CN112569222A (zh) * 2020-12-31 2021-03-30 赣南医学院 三氟淫羊藿素在制备改善疼痛、肿胀及运动功能的药物中的应用
IL307950A (en) 2021-05-03 2023-12-01 Petra Pharma Corp Allosteric chromanone inhibitors of PHOSPHOINOSITIDE 3-KINASE (PI3K) for the treatment of diseases
TWI829179B (zh) 2021-05-27 2024-01-11 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)異位色烯酮抑制劑
TW202329930A (zh) 2021-09-30 2023-08-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑
CN114288312A (zh) * 2022-01-19 2022-04-08 广州中医药大学第一附属医院 宝藿苷i在制备治疗类风湿关节炎以及骨质疏松药物中的应用及药物
CN114601843A (zh) * 2022-03-22 2022-06-10 重庆医科大学附属第一医院 淫羊藿苷在制备治疗自身免疫性葡萄膜炎药物中的用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2516922A1 (fr) * 1981-11-25 1983-05-27 Lipha Acides (oxo-4-4h-(1)-benzopyran-8-yl) alcanoiques, sels et derives, preparation et medicament les contenant
FR2726273B1 (fr) * 1994-10-26 1996-12-06 Adir Nouveaux derives de la diosmetine, leur procede de preparation et les compositions pharmaceutiques les contenant
JPH09301915A (ja) * 1996-05-08 1997-11-25 Sankyo Co Ltd フラボン及びナフタレン誘導体
US5972995A (en) * 1997-10-16 1999-10-26 Children's Hospital Medical Center Of Northern California Compositions and methods for cystic fibrosis therapy
JP2000191544A (ja) * 1998-12-28 2000-07-11 Japan Science & Technology Corp 肝線維化抑制剤
US20020160983A1 (en) * 2001-03-16 2002-10-31 Alberto Bargiotti Substituted benzopyranones as telomerase inhibitors
DE10232595A1 (de) * 2002-07-18 2004-02-05 Merck Patent Gmbh Lichtschutzmittel
DE10244282A1 (de) * 2002-09-23 2004-04-01 Merck Patent Gmbh Zubereitung mit antioxidanten Eigenschaften
CA2502975A1 (en) * 2002-10-22 2004-05-06 Jenken Biosciences, Inc. Chromones and chromone derivatives and uses thereof
JP4471722B2 (ja) * 2004-04-21 2010-06-02 ポーラ化成工業株式会社 夏用の皮膚外用剤
FR2882654B1 (fr) * 2005-03-01 2007-04-27 Servier Lab Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques
US8802638B1 (en) * 2007-01-25 2014-08-12 University Of South Florida Flavonoid treatment of glycogen synthase kinase-based disease
JP2011518174A (ja) * 2008-04-18 2011-06-23 シェノゲン ファーマ グループ リミテッド エストロゲン受容体に関連する疾患を処置するための化合物及び方法
EP2112145A1 (en) * 2008-04-24 2009-10-28 AxoGlia Therapeutics S.A. Chromenone derivatives useful for the treatment of neurodegenerative diseases
JP5424296B2 (ja) * 2008-08-28 2014-02-26 静岡県公立大学法人 フラボン誘導体の製造方法およびシアル酸転移酵素阻害剤
AU2009295948B2 (en) * 2008-09-29 2013-12-05 GlaxoSmithKline, LLC Quinazolinone, quinolone and related analogs as sirtuin modulators
EP2370566A1 (en) * 2008-12-03 2011-10-05 Università Degli Studi Di Torino Isogenic human cell lines comprising mutated cancer alleles and process using the cell lines
JP5534751B2 (ja) * 2009-09-07 2014-07-02 学校法人 名城大学 アンドロゲン受容体アンタゴニスト及びアンドロゲン受容体結合阻害剤
CN102558164B (zh) * 2010-12-31 2016-06-15 北京盛诺基医药科技有限公司 苯并吡喃酮类雌激素受体调节剂
FR3002543A1 (fr) * 2013-02-28 2014-08-29 Servier Lab Procede de synthese enzymatique de flavonoides, et application a la synthese de derives de diosmetine
CN104546822B (zh) * 2013-10-21 2018-07-27 鲁南制药集团股份有限公司 淫羊藿苷元的医药用途
CN103860542A (zh) * 2014-01-22 2014-06-18 贾晓斌 环淫羊藿苷元在制备抗肿瘤组合物中的应用
EP3097088A4 (en) * 2014-01-23 2017-10-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Icariin derivatives

Also Published As

Publication number Publication date
CN109310666A (zh) 2019-02-05
EP3426242A4 (en) 2020-03-18
WO2017156520A1 (en) 2017-09-14
MX2018010993A (es) 2019-01-17
US20200115358A1 (en) 2020-04-16
EP3426242A1 (en) 2019-01-16
AU2017230119A1 (en) 2018-09-27
CA3017366A1 (en) 2017-09-14
KR20180120746A (ko) 2018-11-06
JP2019507796A (ja) 2019-03-22

Similar Documents

Publication Publication Date Title
BR112018068412A2 (pt) composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral
CY1124959T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
CO2019007863A2 (es) Derivados de benzooxazol como inmunomoduladores
CY1125127T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CY1124368T1 (el) Μεθοδοι αυξησης της τονικης αναστολης και θεραπειας του συνδρομου angelman
CY1119676T1 (el) Συνθεσεις και μεθοδοι για τη θεραπεια του καρκινου
BR112018070163A2 (pt) compostos de aminopurina substituída, composições e métodos de tratamento
BR112018009252A2 (pt) tratamento da osteoartrite
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
BR112017019287A2 (pt) composto, composição farmaceuticamente aceitável, método de tratamento de câncer, processo para preparar o composto da fórmula i, método para tratar câncer, e kit
CL2017000290A1 (es) Inhibidores de la proteína kinasa c y métodos de su uso.
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
CY1123216T1 (el) Αναστολεις της gls1 για την αντιμετωπιση νοσων
CY1121554T1 (el) Παραγωγο πυρανοχρωμενυλ-φαινολης, και φαρμακευτικη συνθεση για αγωγη μεταβολικου συνδρομου ή φλεγμονωδους παθησης
BR112016016870A8 (pt) derivados de icariina, seus usos, e composição farmacêutica
BR112017000730A2 (pt) derivados de pirrolidinona como inibidores de metap-2
CY1124907T1 (el) Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
EA201991196A1 (ru) Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов
BR112015023383A2 (pt) compostocomposição farmacêutica; e método de modulação
BR112017020374A2 (pt) compostos bicíclicos fundidos para o tratamento de doença
EA201690376A1 (ru) Ингибиторы дезоксицитидинкиназы
EA201891439A1 (ru) Трициклические соединения и их композиции в качестве ингибиторов киназ
EA202091169A1 (ru) Применяемые в качестве ингибиторов iap миметики smac и их применение

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) [chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements